-- 獨立研究機構CFRA向發布了以下研究報告。 CFRA分析師的觀點摘要如下:我們將NatWest集團的12個月目標價從19美元下調至17美元。我們的目標價是透過將本益比應用於我們2026年的每股盈餘預測得出的。鑑於集團2026年第一季業績報告中凸顯的更為謹慎的近期展望和宏觀經濟風險加劇,我們目前採用的目標本益比為8.0倍,低於先前的9.3倍。儘管我們下調了評級,但我們的觀點仍然總體積極,這主要基於其相對於同行的顯著估值折讓、持續的結構性對沖利好以及已證實的成本控制。然而,鑑於第一季業績報告揭示了新興的宏觀經濟不利因素和特定利潤率壓力,我們對近期展望的謹慎態度有所緩和。儘管透過 Evelyn Partners 進軍財富管理領域的長期策略擴張仍穩健,但我們認為,要實現股價重新評估,目前需要應對這些更為突出的近期挑戰。
Related Articles
Argus Adjusts Price Target on Nasdaq to $103 From $98
Nasdaq (NDAQ) has an average rating of buy and mean price target of $110.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $91.54, Change: $-0.37, Percent Change: -0.40%
Argus Adjusts Price Target on IDEX to $250 From $240
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $214.86, Change: $-2.99, Percent Change: -1.37%
Argus Adjusts Price Target on Thermo Fisher Scientific to $560 From $610
Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $470.05, Change: $-8.91, Percent Change: -1.86%